Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5945
    -0.0005 (-0.08%)
     
  • NZD/EUR

    0.5555
    +0.0015 (+0.27%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.83
    +0.26 (+0.31%)
     
  • GOLD

    2,349.00
    +6.50 (+0.28%)
     
  • NASDAQ

    17,759.86
    +329.36 (+1.89%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,316.28
    +230.48 (+0.61%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.7230
    +1.2270 (+1.33%)
     

Why TransEnterix Is Rising Today

What happened

In response to the company's presentation at the RBC Capital Markets 2018 Global Healthcare Conference, shares of TransEnterix (NYSEMKT: TRXC), a medical device maker focused on robotic surgery, rose as much as 12% in afternoon trading on Wednesday. The rally has since cooled off, but shares are still up about 7% as of 3:25 p.m. EST.

So what

TransEnterix CEO Todd Pope has been presenting at a handful of investor conferences in recent weeks in an effort to build up support for his company's stock. Today's presentation appears to have done the trick.

Durig the presentation, CEO Pope talked in general about the company's commercialization strategy and highlighted a few recent successes that it has had in international markets. He also touched on the company's product roadmap, competition, and the opportunities that lie ahead.

ADVERTISEMENT

Traders clearly liked what CEO Pope had to say, which is why shares rose today.

Microphone in front of group
Microphone in front of group

Image source: Getty Images.

Now what

2018 is going to be a pivotal year for TransEnterix. The pressure is on for the company to show as much commercial traction as possible for its Senhance system. On that front, investors recently learned that the company expects to recognize revenue from two Senhance sales in the current quarter. What's more, the company just submitted for a label expansion claim in the U.S. that should more than double its addressable market opportunity if it gets the green light.

Will TransEnterix's small commercial team be able to wrestle away market share from Intuitive Surgical? It's possible, but I still think that the situation is far too dicey to put any capital at risk. That's why my plan is to watch this story play out from the sidelines.

More From The Motley Fool

Brian Feroldi owns shares of Intuitive Surgical. The Motley Fool owns shares of and recommends Intuitive Surgical. The Motley Fool has a disclosure policy.